Genmab — Juni 2023
-
Det kan selvselvfølgelig være en kombination af flere ting som fik kursen helt ned i 1863 juni 2022. Dennne kombikation er så nu forbedret meget med Epco godkendelse, 12 mrd +35% vækst og udsigt til lavere renter. D.v.s en retracement bung vil ligge en del hæjere end de 1863 sidste og rimlig god mulighed 2650 støtte niveauet holder
-
Tak for gode refleksioner SB. "... så normalt vil et eller andet ske indenfor de næste 6 måneder, hedge fund bust, credit crunch, større banking failure mm" Jeg er helt enig, der kommer en black swan event og renten nedsættes. Det er som regel tegn på at "somethings broken"
-
Dr.
@BenjaminBesseMD
at #ASCO23 discusses biomarkers for amivantamab plus lazertinib for #EGFR NSCLC from CHRYSALIS-2 https://twitter.com/StephenVLiu/status/1664708546913619988 - Full presentation https://www.congresshub.com/Oncology/AM2023/Amivantamab/Besse#slides -
ASCO Daily: Analysis and insight from Friday and Saturday's key presentations https://firstwordpharma.com/story/5747636
-
(Generel orientering).
-
Donation med stor tak for al den gode information, som tilflyder mig. https://www.proinvestor.com/support
-
Janssen Presents Longer-Term Talquetamab Follow-Up Data Showing Overall Response Rates of More Than 70 Percent in Heavily Pretreated Patients with Multiple Myeloma https://www.jnj.com/janssen-presents-longer-term-talquetamab-follow-up-data-showing-overall-response-rates-of-more-than-70-percent-in-heavily-pretreated-patients-with-multiple-myeloma
-
TRiMM-2: Response Rate of 78% Seen in Patients Who Receive Talquetamab With Subcutaneous Daratumumab for Multiple Myleoma https://www.ajmc.com/view/trimm-2-response-rate-of-78-seen-in-patients-who-receive-talquetamab-with-subcutaneous-daratumumab-for-multiple-myleoma
-
Talquetamab + Daratumumab in Patients With Relapsed/Refractory Multiple Myeloma: Updated TRIMM-2 Results https://www.congresshub.com/Oncology/AM2023/Talquetamab/Dholaria
-
Dual Bispecific Combination Teclistamab/Talquetamab Displays High Activity in RRMM https://www.targetedonc.com/view/dual-bispecific-combination-teclistamab-talquetamab-displays-high-activity-in-rrmm
-
-
First Results From the RedirecTT-1 Study With Teclistamab + Talquetamab Simultaneously Targeting BCMA and GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma https://www.congresshub.com/Oncology/AM2023/Teclistamab/Cohen
-
-
New Long-Term Data from the CHRYSALIS Study Show Median Progression-Free Survival Not Reached after 33.6 Months of Follow-Up with First-Line Use of RYBREVANT
(amivantamab-vmjw) and Lazertinib Combination Therapy in Patients with Treatment-Naïve EGFR-Mutated Advanced Non-Small Cell Lung Cancer
Det er i 1L ?Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind